Yutrepia
Yutrepia ingredients
| Active ingredient | Strength |
|---|---|
| Treprostinil Sodium | 26.5 ug/1, 79.5 ug/1, 53 ug/1, 106 ug/1 |
What Yutrepia is used for
The FDA lists the approved uses on the official label (below). In the EU, treprostinil is approved as Trepulmix for:
Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Yutrepia
- Generic name
- Treprostinil
- Made by
- Liquidia Technologies, Inc.
- Forms
- Capsule
- Given
- Respiratory (Inhalation)
- Drug class
- Prostacycline Vasodilator
- FDA approval
- New drug application (NDA) NDA213005
- On the US market since
- 2025
Official information
- Yutrepia prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Treprostinil)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yutrepia?
Yutrepia (Treprostinil) is a specialist medicine made by Liquidia Technologies, Inc., approved by the US FDA.
What are the ingredients of Yutrepia?
Yutrepia contains Treprostinil Sodium (26.5 ug/1, 79.5 ug/1, 53 ug/1, 106 ug/1).
Is Yutrepia approved in Europe?
The same active substance is approved in the EU as Trepulmix.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA